booster dose mrna-1273 (Moderna)
90
Structured Review
Moderna
booster dose mrna-1273
Booster Dose Mrna 1273, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-1273+booster+dose/mrna+1273/pmc11807006-53-11-14
Average 90 stars, based on 1 article reviews
Booster Dose Mrna 1273, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-1273+booster+dose/mrna+1273/pmc11807006-53-11-14
Average 90 stars, based on 1 article reviews
booster dose mrna-1273 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Infection:Article Title: Homologous and Heterologous Covid-19 Booster Vaccinations Article Snippet: # Page and Section of V3.0 Originally in Version 2.0 Updated in Version 3.0 Rationale for change 33 Page 28, Section 4.1, Overall Design, Summary of Treatment Arms New Added • 7E - Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous platform delayed dose of BNT162b2 • 8E - Evaluates mRNA-1273 EUA vaccination series followed by a homologous platform delayed dose of BNT162b2 • 9E - Evaluates BNT162b2 EUA vaccination series followed by a homologous platform delayed dose of BNT162b2 • 10E- Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous platform delayed dose of a combined homologous and variant spike lineage mRNA-1273.211 • 11E - Evaluates BNT162b2 EUA vaccination series followed by a homologous platform delayed dose of a combined homologous and variant spike lineage mRNA-1273.211 o Note – the homologous comparator for groups 10E and Article Title: Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters Article Snippet: Case 2 demonstrating dermatographism 3 weeks after administration of the Article Title: Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students. Article Snippet: BACKGROUND AND OBJECTIVES: Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents in congregate settings remains important.. We evaluated protection against SARS-CoV-2 infection using school-based testing data.. METHODS: Using data from Utah middleand high-school students participating in school-wide antigen testing in January 2022 during omicron (BA.1) variant predominance, log binomial models were fit to estimate the protection of previous SARS-CoV-2 infection and coronavirus disease 2019 vaccination against SARS-CoV-2 infection. Transmission Assay:Article Title: Homologous and Heterologous Covid-19 Booster Vaccinations Article Snippet: # Page and Section of V3.0 Originally in Version 2.0 Updated in Version 3.0 Rationale for change 33 Page 28, Section 4.1, Overall Design, Summary of Treatment Arms New Added • 7E - Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous platform delayed dose of BNT162b2 • 8E - Evaluates mRNA-1273 EUA vaccination series followed by a homologous platform delayed dose of BNT162b2 • 9E - Evaluates BNT162b2 EUA vaccination series followed by a homologous platform delayed dose of BNT162b2 • 10E- Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous platform delayed dose of a combined homologous and variant spike lineage mRNA-1273.211 • 11E - Evaluates BNT162b2 EUA vaccination series followed by a homologous platform delayed dose of a combined homologous and variant spike lineage mRNA-1273.211 o Note – the homologous comparator for groups 10E and Article Title: Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters Article Snippet: Case 2 demonstrating dermatographism 3 weeks after administration of the Article Title: Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students. Article Snippet: BACKGROUND AND OBJECTIVES: Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents in congregate settings remains important.. We evaluated protection against SARS-CoV-2 infection using school-based testing data.. METHODS: Using data from Utah middleand high-school students participating in school-wide antigen testing in January 2022 during omicron (BA.1) variant predominance, log binomial models were fit to estimate the protection of previous SARS-CoV-2 infection and coronavirus disease 2019 vaccination against SARS-CoV-2 infection. |